First most-favored-nation manufacturer deal announced

The Trump administration announced its first most-favored-nation (MFN) pricing agreement with a pharmaceutical manufacturer on September 30, 2025, the opening deal in a series that had grown to 16 manufacturer agreements by February 2026 ^[1]. The MFN approach ties U.S. prices for certain drugs to the lowest prices paid by other developed nations ^[1].

The first deal came months after President Trump signed an executive order on May 12, 2025, called "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which directed the administration to pursue lower U.S. drug prices in line with those in comparable countries ^[1]. On July 31, 2025, the president sent letters to major drug manufacturers outlining steps they needed to take to bring prices down ^[1]. The September 30 agreement was the first manufacturer to sign on following that outreach ^[1].

By the time the administration launched TrumpRx.gov on February 5, 2026, five manufacturers — AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer — had reached deals that translated into discounts available through the new website, with drugs from additional companies expected in the coming months ^[1]. Among the medicines featured at launch were Ozempic and injectable Wegovy, both made by Novo Nordisk, and Zepbound, made by Eli Lilly ^[1].

According to the White House fact sheet, the monthly price of Ozempic was set to fall from $1,028 to an average of $350, with prices as low as $199 depending on dosage strength ^[1]. Injectable Wegovy was set to drop from $1,349 to an average of $350, also as low as $199 depending on strength, while the Wegovy pill was set to fall from $1,349 to as low as $149 ^[1]. Zepbound's monthly price was set to fall from $1,088 to an average of $346, with prices as low as $299 depending on dosage ^[1]. The fact sheet described Ozempic and Wegovy together as the two drugs with the highest annual spending in the United States ^[1].

Why it matters for patients

For patients currently paying list price for these GLP-1 medications, the gap between old and new prices described in the fact sheet is substantial — potentially hundreds of dollars per month depending on the drug and dosage ^[1]. But access to these discounts runs through a specific channel: TrumpRx.gov, using coupons or manufacturer-run programs that require a valid prescription ^[1]. The sources here do not describe how these prices interact with existing insurance coverage, Medicare, or Medicaid, so patients with those types of coverage do not yet know from this information whether or how the discounts apply to them.

It's also not yet clear from available sources exactly which dosage strengths qualify for the lowest advertised prices versus the average prices, since the fact sheet notes savings vary "depending on dosage strength" without specifying further ^[1]. Patients considering whether these prices affect their own costs will need more detail than is available in this announcement alone.

What happens next

The administration said additional drugs from other manufacturers that have signed MFN deals would be added to TrumpRx.gov in the coming months after the February 5, 2026 launch ^[1]. The fact sheet also referenced a December 1, 2025 agreement with the United Kingdom intended to raise UK drug prices by 25%, which the administration framed as part of the broader MFN strategy of getting other countries to pay more so U.S. prices could fall ^[1]. Separately, on January 15, 2026, President Trump called on Congress to pass what the fact sheet called "The Great Healthcare Plan," which would aim to codify MFN savings into law alongside other insurance changes, though the sources do not indicate whether Congress has acted on that request ^[1].